Q: Do you still lose weight on a microdose
In adults with obesity or overweight with 1 weight-related comorbidity, along with diet and exercise, A well-studied safety profile: Pooled safety data from 3 weight-management clinical trials evaluating Wegovy 2.4 mg pen 1 6.8% of patients treated with Wegovy and 3.2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions 1 Permanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in 4.3% of patients treated with Wegovy vs 0.7% of patients treated with placebo 1 The most common adverse reactions leading to discontinuation were: Nausea (1.8% vs 0.2%) , vomiting (1.2% vs 0%) , and diarrhea (0.7% vs 0.1%) for Wegovy and placebo, respectively 2 *Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort, and epigastric discomfort
This is not a one size fits all program
Since then, sales of the drug have skyrocketed to the point that it is now used widely throughout the U.S
It also prevents the metabolism of CJC-1295, further prolonging the duration of action
Blood tests may show increased bilirubin, alkaline phosphatase, GGT, ALT, AST, or white blood cells when biliary obstruction or inflammation is present